Full Press Release Details
Atara Bio Announces First Quarter 2016 Financial Results and Recent Highlights
SOUTH SAN FRANCISCO, Calif., May 5, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific innovation, today reported financial results for the first quarter ended March 31, 2016 and recent operational highlights.
"We continue to advance our allogeneic T-cell therapy platform, including our EBV, CMV and WT1 product candidates," said Isaac Ciechanover, Chief Executive Officer and President of Atara Bio. "This quarter we prepared for the initiation of our upcoming expanded access trial for our EBV-CTLs and advanced our discussions with the FDA for the planned pivotal trials and associated manufacturing. We have also continued our discussions with EMA regarding late stage development to support registration. In addition, we have expanded our efforts beyond hematologic malignancies to EBV-related solid tumors such as nasopharyngeal carcinoma as well as autoimmune conditions."
Recent Highlights and Upcoming Milestones
First Quarter 2016 Financial Results
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. is a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific innovation, with an initial focus on immunotherapy and oncology. Atara Bio's programs include T-cell product candidates and molecularly targeted product candidates. The T-cell product candidates include EBV-CTL, CMV-CTL and WT1-CTL and harness the power of the immune system to recognize and attack cancer cells and cells infected with certain viruses. The molecularly targeted product candidates include STM 434. These product candidates target activin and myostatin, members of the TGF-beta family of proteins, and have demonstrated the potential to have therapeutic benefit in a number of clinical indications.
Forward-Looking Statements
This press release contains or may imply "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. For example, forward-looking statements include statements regarding the initiation of a multi-center expanded access trial of EBV-CTL at transplant centers in the U.S. in the second quarter of 2016, commencement of two pivotal clinical trials of EBV-CTL for rituximab-refractory EBV-PTLD following HCT as well as SOT towards the end of 2016, the intent to seek scientific advice from the EMA later this year, the intent to commence a pivotal trial for the treatment of CMV infection in 2017, the belief that cash and investments as of March 31, 2016 will be sufficient to fund the Company's planned operations through 2018, data presentations during the upcoming ASCO Annual Meeting, and the applicability of these results to allogeneic product development through the Atara-QIMR Berghofer collaboration. Because such statements deal with future events and are based on Atara Bio's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Atara Bio could differ materially from those described in or implied by the statements in this press release. These forward-looking statements are subject to risks and uncertainties, including those discussed under the heading "Risk Factors" in Atara Bio's annual report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 4, 2016, including the documents incorporated by reference therein, and subsequent filings with the SEC. Except as otherwise required by law, Atara Bio disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.
Atara Biotherapeutics, Inc.
Consolidated Balance Sheets
| March 31, | December 31, | |||
| 2016 | 2015 | |||
| Assets | ||||
| Current assets: | ||||
| Cash and cash equivalents | $ 22,056 | $ 23,746 | ||
| Short-term investments | 284,347 | 296,736 | ||
| Restricted cash | 194 | 194 | ||
| Prepaid expenses and other current assets | 5,144 | 3,921 | ||
| Total current assets | 311,741 | 324,597 | ||
| Property and equipment, net | 1,148 | 270 | ||
| Other assets | 89 | 108 | ||
| Total assets | $ 312,978 | $ 324,975 | ||
| Liabilities and stockholders' equity | ||||
| Current liabilities: | ||||
| Accounts payable | $ 1,896 | $ 1,445 | ||
| Accrued compensation | 1,337 | 2,624 | ||
| Accrued research and development expenses | 4,430 | 5,112 | ||
| Other accrued liabilities | 1,197 | 528 | ||
| Total current liabilities | 8,860 | 9,709 | ||
| Long-term liabilities | 284 | 166 | ||
| Total liabilities | 9,144 | 9,875 | ||
| Commitments and contingencies | ||||
| Stockholders' equity: | ||||
| Common stock | 3 | 3 | ||
| Additional paid-in capital | 418,451 | 413,725 | ||
| Accumulated other comprehensive income (loss) | 51 | (518) | ||
| Accumulated deficit | (114,671) | (98,110) | ||
| Total stockholders' equity | 303,834 | 315,100 | ||
| Total liabilities and stockholders' equity | $ 312,978 | $ 324,975 |
Atara Biotherapeutics, Inc.
Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share amounts)
| Three Months Ended March 31, | |||
| 2016 | 2015 | ||
| Operating expenses: | |||
| Research and development | $ 11,247 | $ 5,767 | |
| General and administrative | 5,814 | 3,544 | |
| Total operating expenses | 17,061 | 9,311 | |
| Loss from operations | (17,061) | (9,311) | |
| Interest and other income, net | 503 | 153 | |
| Loss before provision for income taxes | (16,558) | (9,158) | |
| Provision for income taxes | 3 | 2 | |
| Net loss | $ (16,561) | $ (9,160) | |
| Other comprehensive loss: | |||
| Unrealized gain on available-for-sale securities | 569 | 82 | |
| Comprehensive loss | $ (15,992) | $ (9,078) | |
| Net loss per common share: | |||
| Basic and diluted net loss per common share | $ (0.58) | $ (0.42) | |
| Weighted-average common shares outstanding used to calculate basic and diluted net loss per common share | 28,541,896 | 21,918,467 |
INVESTOR & MEDIA CONTACT:
| Investors: | Media: |
| Steve Klass | Justin Jackson |
| 212-213-0006 x331 | 212-213-0006 x327 |
| sklass@burnsmc.com | jjackson@burnsmc.com |